Elisa A. Rozeman
The Netherlands Cancer Institute(NL)University Medical Center Utrecht(NL)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Clusterin in disease pathology, CAR-T cell therapy research, S100 Proteins and Annexins, Immunotherapy and Immune Responses
Most-Cited Works
- → B cells and tertiary lymphoid structures promote immunotherapy response(2020)2,551 cited
- → The human tumor microbiome is composed of tumor type–specific intracellular bacteria(2020)2,260 cited
- → Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma(2018)1,117 cited
- → Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma(2018)843 cited
- → Identification of CMTM6 and CMTM4 as PD-L1 protein regulators(2017)693 cited
- → Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers(2019)540 cited
- → Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial(2019)507 cited
- → Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)(2021)418 cited
- → Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial(2022)332 cited
- → Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma(2021)325 cited